본문으로 건너뛰기
← 뒤로

Machine Learning Predicts Adequacy of Rapid On-site Evaluation in Fine Needle Aspirations in Lung Cancer Cytology.

The American journal of pathology 2026

Brechenmacher C, Kezlarian B, Weirich G, Botelho S, Wangsaroj B, Buonocore D, Schüffler PJ

📝 환자 설명용 한 줄

Lung cancer is projected to become the leading cause of cancer-related mortality in both smoking and nonsmoking populations.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Brechenmacher C, Kezlarian B, et al. (2026). Machine Learning Predicts Adequacy of Rapid On-site Evaluation in Fine Needle Aspirations in Lung Cancer Cytology.. The American journal of pathology. https://doi.org/10.1016/j.ajpath.2026.03.004
MLA Brechenmacher C, et al.. "Machine Learning Predicts Adequacy of Rapid On-site Evaluation in Fine Needle Aspirations in Lung Cancer Cytology.." The American journal of pathology, 2026.
PMID 41862018

Abstract

Lung cancer is projected to become the leading cause of cancer-related mortality in both smoking and nonsmoking populations. Rapid on-site evaluation (ROSE) of fine needle aspiration specimens is essential for timely diagnosis and procedural decision-making during lung cancer assessment. A machine learning pipeline was developed for cell-based adequacy assessment and lesion detection that integrates automated cell detection, convolutional neural network-based cell classification, and slide-level aggregation using a random forest model. On held-out test data, binary classifiers for lymphocytes and tumor cells achieved accuracies of 91.5% and 92.7% with recalls of 92.6% and 93.1%, respectively. The end-to-end ROSE system demonstrated class accuracies of 82% to 85%, comparable with human cytologist performance, and a lesion-focused classifier reached a recall of 92.0%. These findings indicate that machine learning-based cell analysis can support ROSE by expediting adequacy assessment and improving diagnostic yield during transbronchial needle aspiration procedures.